The status of antisense oligodeoxynucleotides as therapeutic agents

International Journal of Pharmaceutical Medicine

Volumn 11, Issue 5, 1997, Pages 263-268

  Walker, Todd L ^a   Dass, C R ^a   Burton, M A ^a   DeCruz, E E ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Antisense; Gene therapy; Therapeutics

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FORMIVERSEN; GENE EXPRESSION MODULATOR 132; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN KINASE C; RAS PROTEIN; TRECOVIRSEN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CANCER; CHEMICAL MODIFICATION; DRUG DEVELOPMENT; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOXICITY; EYE INFLAMMATION; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTOXICITY; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETINITIS; REVIEW; TRANSLATION REGULATION; VISUAL DISORDER;

EID: 0031467864     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004.
2. Minshull J, Hunt T. The use of single-stranded DNA and RNase H to promote quantitative "hybrid arrest of translation" of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Research 1986; 14: 6433-51.
3. Han J, Zhu Z, Hsu C, Finley, W. Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence. Antisense Research and Development 1994; 4: 53-65.
4. Uhlmann E, Peymann A. Antisense oligonucleotides: a new therapeutic principle. Chemical Reviews 1990; 90: 543-544.
5. Froehler B, Ng P, Matteucci M. Phosphoramidate analogues of DNA: Synthesis and thermal stability of hetroduplexes. Nucleic Acid Research 1988; 16: 4831-4839.
6. Furdon PJ, Dominski Z, Kole R. RNase H cleavage of RNA hybridised to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acid Research 1989; 17: 9193-9204.
7. Agrawal S, Goodchild J, Civera MP, Thornton AH, Sarin PS, Zamecnik PC. Oligonucleotide phosphoramidates and phosphorothioates as inhibitors of the immunodeficiency virus. Proceedings of the National Academy of Science USA 1988; 85: 7079-7083
8. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleotides phosphorothioate stability in subcellular extracts, culture media, sera, and cerebrospinal fluid. Journal of Biochemical and Biophysical Methods 1990; 20: 259-267.
9. Stein CA, Shinozuka K, Subasinghe C, Cohen JS Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acid Research 1988; 16: 3209-3221.
10. Stein CA Cohen, JS Phosphorothioate oligodeoxynucleotide analogues, in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Cohen JS (ed.): Boca Raton, Fl.: CRC Press, 1989, p97.
11. Zon G. Antisense phosphorothioate oligodeoxynucleotides - introductory concepts and possible molecular mechanisms of toxicity. Toxicology Letters 1995; 82-3: 419-424.
12. Iversen PL, Copple BL, Tewary HK. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicology Letters 1995; 82-3: 425-430.
13. Sarmiento UM, Perez JR, Becker JM, Narayanan R. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Research and Development 1994; 4: 99-107.
14. Leonetti C, D'Agnano I, Lozupone F, Valentini, A, Geiser T, Zon G, Calbretta B, Citro G, Zupi G. Antitumour effect of c-myc antisense phosphorothioate oligonucleotides on human melanoma cells in vitro and in mice. Journal of the National Cancer Institute 1996; 88: 419-429
15. Maltese JY, Sharma HW, Vassilev L, Narayanan R. Sequence context of antisense RelA/NK-kB phosphorothioates determines specificity. Nucleic Acids Research 1995; 23: 1146-1151.
16. Tamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to nduce interferon production and augment natural killer cell activity is associated with their base length. Antisense Research and Development 1994; 4: 119-122.
17. Hutcherson SL, Palastine AG, Cantrill HL. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients. 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1996, Abs 204.
18. ISIS Pharmaceuticals. Press Release: ISIS confirms safety and efficacy of antisense CMV retinitis compound; Phase III studies are ongoing. ISIS Pharmaceutical, Carlsbad, CA, September 1996.
19. Zhang RW, Yan JM, Shahinian H, Amin G, Lu ZH, Liu TP, Saag MS, Jiang ZW, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligonucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clinical Pharmacology and Therapeutics 1995; 58: 44-53.
20. Serini D, Katlama C, Vilde JL et al. An open-label multidose safety, pharmacokinetic and preliminary antiviral activity study of GEM 91 administered by intermittent intravenous infusion in HIV-positive adults 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1996, Abs 1.
21. Vandestolpe A, Vandersaag PT. Intercellular adhesion molecule-1 [Review]. Journal of Molecular Medicine 1996; 74: 13-33.
22. Crooke ST. Progress in the development of antisense drugs. Expert Opinions in Investigative Drugs 1996; 5: 1047-1052.
23. Perletti GP, Monti E. PKCs transducers of critical signals in cancer cells. International Journal of Oncology 1996; 9: 171-177.
24. Sikic B. Stanford university investigator presents promising Phase I results of ISIS anticancer drug at ASCO. Internet Site: http://wwwmed.stanford.edu/center/communications/pressrel/May97/ antisense.html, 20 May 1997.
25. Fontana D, Bellma M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F, Russo R, Leonardo E. Evaluation of c-fas oncogene product (p21) in superficial bladder cancer. European Urology 1996; 29: 470-476.
26. Field K. GEM 132: An advanced chemistry oligonucleotides for antisense treatment of HCMV. Internet site: http://www.hybridon.com. 1996
27. Bishop R, Iversen PL, Bayeve E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. Journal of Clinical Oncology 1996; 14: 1320-1326.
28. Wyatt JR, Vickers TA, Robertson JL, Buckheit RW, Klimkait T et al. Combinationally selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proceedings of the National Academy of Science USA 1994; 95: 1356-1360.
29. Ramanathan M, Lantz M, MacGregor RD, Garovoy MR, Hunt CA. Characterisation of the oligonucleotide mediated inhibition of interferon g-receptor major histocompatibility complex class I and intracellular adhesion molecule-1. Journal of Biological Chemistry 1994; 269: 24564-24574.
30. 2 enzyme activity by phosphorothioate oligonucleotides. Nucleic Acids Research 1994; 22: 3202-3209.
31. Watson PH, Pon RT, Shiu RPC. Inhibition of cell adhesion to plastic substratum by phosphorothioate oligonucleotide. Experimental Cell Research 1992; 202: 391-397.
32. Yaswen P, Stampler MR, Ghosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Research 1993; 3: 67-77.
33. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SSF, Kramer TB et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proceedings of the National Academy of Science USA 1995; 92: 4051-4055.
34. Stein CY. Does antisense exist? Nature Medicine 1995; 11: 1119-1121.
35. Stein CY. Phosphorothioate antisense oligonucleotides: questions of specificity. Trends in Biotechnology 1996; 14: 147-148.
36. Olivas WM, Mather LJ. Competitive triplex/quadruplex equilibria involving guanine rich oligonucleotides. Biochemistry 1995; 34: 278-284.
37. Agrawal S. Antisense oligonucleotides: Towards clinical trials. Trends in Biotechnology 1996; 14: 376-386.
38. Agrawal S, Jaing ZW, Zhao QY, Shaw D, Cai QY, Roskey A, Channavajjala L, Saxinger C, Zhang RW. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides - in vitro and in vivo studies. Proceedings of the National Academy of Sciences USA 1997; 94: 2620-2625.
39. Altmann KH, Dean N, Fabbro D, Frierer SM, Geiger T, Härter R et al. Second generation antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia 1996; 50: 168-176.
40. Crooke ST, Bernstein LS, Boswell H. Progress in the development and patenting of antisense drug discovery technology. Expert Opinions in Therapeutic Patents 1996; 6: 855-870.
41. Bock LC, Griffin LC, Latham, JA, Vermaas EH, Toole JJ. Selection of single stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-566.
42. Perez JR, Li Y, Stein CA, Majumder S, Van Ooschot, Narayanan, R. Sequence independent induction of the Spl transcription factor activity by phosphorothioate oligodeoxynucleotides. Proceedings of the National Academy of Science USA 1994; 91: 5957-5961.
43. Gao W-Y, Hans F-S, Storm C, Egan W, Cheng Y-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Molecular Pharmacology 1992; 41: 223-229.
44. Clark DL, Chrisey LA, Campbell J, Davidson EA. Non-sequence specific antimalarial activity of oligonucleotides. Molecular Biochemistry and Parasitology 1994; 63: 129-134.
45. Ho PTC, Ishiguro K, Wickstrim E, Sartorelli AC. Non-sequence-specific inhibition of transterrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Research and Development 1991; 1: 329-342.
46. Chrisey LA, Pazirandeh M, Liss HS. Non-sequence-specific inhibition of bacterial luminescence by phosphorothioate oligodeoxyribonucleotides. Antisense Research and Development 1995; 5: 261-9.
47. Abraham WC, Logan B, Thompason VL, Williams JM, Tate WP. Sequence-independent effects of phosphorothioated on synaptic transmission and excitability in the hippocampus in vivo. Neuropharmacology 1997; 36: 345-352.
48. Yakubov L, Khaled Z, Zhang LM, Truneh A, Vlassov V, Stein CA. Oligonucleotides interact with recombinant CD4 at multiple sites. Journal of Biological, Chemistry 1993; 268: 18818-18823.
49. Guvakova MA, Yakubov LA, Vlodavsky J, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors and remove it from low affinity binding sites on extracellular matrix. Journal of Biological Chemistry. 1995; 270: 2620-2627.